Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.62 |
| ▸ | MET | P08581 | 12/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21431794 | 0.83 | AXL (0.86) | AXLMET | |
| SCHEMBL21408234 | 0.83 | AXL (0.85) | AXL | |
| SCHEMBL30216609 | 0.83 | AXL (0.85) | AXL | |
| SCHEMBL21431801 | 0.81 | AXL (0.77) | AXL | |
| SCHEMBL4365490 | 0.81 | AXL (0.62) | AXLMETKDR | |
| SCHEMBL30216655 | 0.81 | AXL (0.77) | AXL | |
| SCHEMBL9987209 | 0.79 | MET (0.62) | AXLMETKDR | |
| SCHEMBL12335707 | 0.79 | MET (0.70) | AXLMETKDRFLT3 | |
| SCHEMBL19711775 | 0.79 | MET (0.62) | AXLMETKDR | |
| SCHEMBL1472355 | 0.79 | AXL (0.61) | AXLMETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2125780-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200464-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | AXL 578/4885MET 3/4885KDR 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.